Drug Briefing: Avacopan

Views: 28     Author: Site Editor     Publish Time: 2024-05-10      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
sharethis sharing button

Query Drug:Avacopan

Query Time:2024-06-04 09:21:05

*** Disclaimer *** The information provided here is sourced from resources such as, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

About the Drug

Avacopan (Tavneos) is used to treat two forms of ANCA-associated vasculitis, both granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Avacopan is an add-on treatment used with other medicines for adults with active and severe symptoms.

Avacopan works by blocking a receptor in the blood called complement 5a (or C5a), which is part of the immune system. When Avacopan blocks the C5a receptor it may help reduce blood vessel inflammation, improving disease symptoms.  Avacopan is called a complement 5a receptor (C5aR) antagonist.

Avacopan FDA approval was received on October 7, 2021, under the brand name Tavneos by ChemoCentryx, Inc.  Tavneos is FDA-approved as a treatment for adults with severe active ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) when used together with standard therapy including glucocorticoids.

Anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis) is a rare autoimmune disease that causes inflammation and damage to small or medium-sized blood vessels, affecting various organs, including airways, kidneys, and lungs. Two forms of ANCA-associated vasculitis are granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)

Granulomatosis with polyangiitis (GPA), previously called Wegener’s granulomatosis, mainly affects the respiratory tract and the kidneys, leading to sinusitis, nosebleeds, and kidney disease.

Related Diseases

Extra Information on Drug and Diseases

Drug avacopan

RXCUI: 2572100

May Treat

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Similar Drugs

[may_treat] Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Source MEDRT

[Physiological Effect] Decreased Complement Activity

Source: MEDRT

[Mechanism of Action] Complement 5 Inactivators

Source MEDRT

[Mechanism of Action] Cytochrome P450 3A4 Inhibitors


[Mechanism of Action] Cytochrome P450 3A4 Inhibitors


[Phamacological Category] Complement 5a Receptor Antagonist


[Phamacological Category] Complement 5a Receptor Antagonist


[Mechanism of Action] Complement 5a Receptor Antagonists


[Mechanism of Action] Complement 5a Receptor Antagonists


Orange Book

[Last update] 2024-05-21


Avacopan's Innovator is CHEMOCENTRYX INC

Drug Products

The unique dosage forms from the innovator include:1. CAPSULE;ORAL.

Index Route Brand Name Labeler Approval Date Dosage

Drug Patents

This drug still has 4 effective patents.

Patent Number Submission Date Expiration Date Drug Substance Patent? Drug Product Patent?
8906938 Nov 3, 2021 Dec 21, 2029 Y Y
8445515 Nov 3, 2021 Feb 3, 2031 Y Y
11603356 Apr 14, 2023 May 29, 2041 Y Y
11951214 Apr 26, 2024 Nov 27, 2039

Avacopan Patent Scope

Related Company's Product Pipelines

The innovator CHEMOCENTRYX INC's portolio contains products with the following 1 API(s): AVACOPAN

The above products are related to 1 diseases: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

CHEMOCENTRYX INC_combined_chart_2024-06-04